News - Page 77 - Psychedelic Alpha

Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.

Read more about the article atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression

atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression

Post published:January 6, 2023
Post category:Press Release

Read more about the article atai’s PCN-101 Candidate Fails to Meet Primary Endpoint in Heavily-Anticipated Phase 2a Trial

atai’s PCN-101 Candidate Fails to Meet Primary Endpoint in Heavily-Anticipated Phase 2a Trial

Post published:January 6, 2023
Post category:Analysis

Read more about the article Reunion Neuroscience Inc. Provides 2023 Corporate Update

Reunion Neuroscience Inc. Provides 2023 Corporate Update

Post published:January 6, 2023
Post category:Press Release

Read more about the article FILAMENT HEALTH ANNOUNCES CEO YEAR END LETTER AND CHANGE TO BOARD OF DIRECTORS

FILAMENT HEALTH ANNOUNCES CEO YEAR END LETTER AND CHANGE TO BOARD OF DIRECTORS

Post published:January 5, 2023
Post category:Press Release

Read more about the article Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Post published:January 5, 2023
Post category:Press Release

Read more about the article Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial

Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial

Post published:January 5, 2023
Post category:Press Release

Read more about the article Confirmatory Phase 3 Trial of MDMA Therapy for PTSD is “Successful”, Says MAPS

Confirmatory Phase 3 Trial of MDMA Therapy for PTSD is “Successful”, Says MAPS

Post published:January 5, 2023
Post category:Announcements

Read more about the article Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company’s Psychedelic DMT Stroke Program; Files Form 1-A Offering Statement with U.S. SEC for Regulation A+ Offering

Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company’s Psychedelic DMT Stroke Program; Files Form 1-A Offering Statement with U.S. SEC for Regulation A+ Offering

Post published:January 3, 2023
Post category:Press Release

Read more about the article Clearmind Medicine Announces Shareholders Meeting Results

Clearmind Medicine Announces Shareholders Meeting Results

Post published:December 29, 2022
Post category:Press Release

Read more about the article Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder

Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder

Post published:December 28, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.